Navigation Links
Commissions in Medical News

BTIG To Hold 7th Commissions for Charity Day

anticipated donationS to benefit local charities NEW YORK, May 18 /PRNewswire/ -- BTIG LLC, an institutional broker dealer specializing in trading and related brokerage services, will donate equity and derivative trading commission profits earned on Tuesday, May 19 to a group of nonprofit or...

AHIP Statement on New CMS Guidelines for Agent and Broker Commissions in Medicare Advantage

WASHINGTON, Nov. 10 /PRNewswire-USNewswire/ -- Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), today issued the following statement on new guidelines announced by CMS on agent and broker compensation for Medicare Advantage plans: "We commend CMS for taking this i...

SAFC Pharma Commissions HPAPI Conjugates Facility at St. Louis

ST. LOUIS, Sept. 29 /PRNewswire-FirstCall/ -- SAFC Pharma(TM), a focus area within SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL ), today announced details of a new suite that has been commissioned at its St. Louis campus that will produce high-potency active pharmaceutical ingre...

San Antonio Community Hospital Commissions Leksell Gamma Knife(R) Perfexion(TM) To Serve Over 3 Million Californians

ATLANTA, June 3 /PRNewswire/ -- Physicians at California's San Antonio Community Hospital in Upland, will soon treat patients using the new Leksell(R) Gamma Knife Perfexion(TM). A revolutionary alternative to traditional open-brain surgery and daily radiation treatments, Leksell Gamma Knife Pe...

Chiefs Of Regional Commissions For Animal Health Announced

Dr. Robert Thwala, the Ministry of Agriculture Director of Veterinary and Livestock Services, was anointed as President of the African Regional Commission //for the International Committee of the World Organisation for Animal Health (OIE). Dr. Barry O’Neil was earlier elected the President of...

MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

...fering of 3,500,000 shares of its common stock at a public offering price of $9.70 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $31.4 million. MAP Pharmaceuticals has granted the underwriters of the offering a 30-day option to purc...

NHP Reports 2009 Second Quarter Results

...ation 756 777 1,570 1,524 Lease commissions and tenant and capital improvements (1,343) (1,047) ... Deferred finance cost amortization 3,120 3,120 Lease commissions and tenant and capital improvements (5,608) (5,...

West Announces Second Quarter 2009 Results

... increase included additional spending on information systems, including depreciation and other project-related costs, and outside services, including commissions and acquisition-related legal services. Research spending was substantially unchanged from the prior-year quarter. Resulting operating profit was $34...

Hospira Reports Second-Quarter 2009 Results

... $402.0 $338.3 Trade accounts payable 200.4 231.5 Salaries, wages and commissions 121.2 144.7 Deferred income taxes - 1.5 Other accrued liabilities ...

Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants

... overallotment option. The Company received approximately $40.3 million in net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses. Each warrant has an exercise price of $1.70 per warrant share, for total potential additional gross proceeds t...
Commissions in Medical Technology

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...

Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...

Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers

...on for our products or product candidates. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...

Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer

...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...

PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate

... for our products or product candidates. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...

U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)

...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...

Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement

...ly market products, and other factors which may be beyond the control of either Transition or Lilly. Please see Transition's filings with the Canadian commissions and Lilly's filings with the U.S. Securities and Exchange Commission for further information about risk factors and other cautionary statements. Neith...

Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement

...n Stock at a price of $0.65 per share resulting in gross proceeds of $650,000. WestPark Capital, Inc. acted as placement agent and received $65,000 in commissions and $26,000 representing a non-accountable expense fee. Lixte also issued to WestPark five year warrants to purchase up to 100,000 shares of the Compa...
Commissions in Biological News

Britain's last Neanderthals were more sophisticated than we thought

...s south east England. The project now aims to prospect more widely across the region for similar sites. Barney Sloane, Head of Historic Environment commissions at English Heritage, said: "Sites such as this are extremely rare and a relatively little considered archaeological resource. Their remains sit at a k...

Unmanned aircraft to study Southern California smog and its consequences

...g effects for the first time over California, and this data will likely help California reduce its global warming commitment. The California Energy commissions Public Interest Energy Research (PIER) program will employ CAPPS results in an analysis of the potential future economic and ecological consequences o...

Proposal to step up cardiovascular disease research

... existing projects, and in particular the European Vascular Genomics Network (EVGN), which has been running since January 2004 as part of the European commissions FP6 framework research programme. EVGN has been promoting multidisciplinary interaction between 30 world class basic and clinical institutions in 11 E...

Tiny fish can yield big clues to Delaware River health

...e new habitats for the bridle shiner. The results of the Academys studies, which will continue into 2008, will factor into the Delaware River Basin commissions flow management plans for the river. Bridle shiner prefer slow-moving, shallow waters that flow over beds of aquatic plants. The Upper Delaware River ...
Commissions in Biological Technology

PEAT International Commissions Plasma-Based Waste Treatment Facility Designed Specifically for Onsite Waste Processing

- Marks the first deployment of the system intended for hospitals and industrial facilities - NORTHBROOK, Ill., and ANKLESHWAR, India, April 23 /PRNewswire/ -- PEAT International, Inc., ("PEAT") a global leader in plasma-based waste remediation solutions, announced toda...

Exciton Technologies receives FDA approval to market exSALT(TM)

...sequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue relia...

Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock

...ounced the pricing of an underwritten offering of 7,248,936 shares of its common stock at a price of $3.14 per share. After underwriting discounts and commissions and estimated offering expenses, the company expects to receive net proceeds of approximately $21.2 million. All of the shares are being sold by Iden...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...

Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results

...general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...

Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)

...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...

Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters

... of $7.50 per share, resulting in expected net proceeds to the company of approximately $81.6 million (after payment of the underwriting discounts and commissions and estimated expenses). Leerink Swann LLC acted as sole book-running manager for the offering. Lazard Capital Markets LLC, Canaccord Adams ...

Cell Therapeutics, Inc. Announces Exercise of Overallotment

...common stock, for aggregate gross proceeds of approximately $43.9 million. The net proceeds to the Company after deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $40.3 million. Each warrant has an exercise price of $1.70 per warrant share...

Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement

...irstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement on Form S-3 with the United States Securities and Exchange Commission...

Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

...954 additional shares of its common stock to cover overallotments, if any. The net proceeds to the Company after deducting underwriting discounts and commissions and estimated offering expenses, excluding any exercise of the underwriter's overallotment option, are expected to be approximately $35.0 million. ...
Other Tags
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
Other Contents